2339-59-5

Usage

Uses

Used in Organic Synthesis:
4-FLUORO-BENZAMIDINE HCL H2O is used as a synthetic building block for the development of new organic compounds. Its application in this field is due to its versatile chemical properties, which allow it to be easily integrated into a wide range of chemical reactions and processes.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-FLUORO-BENZAMIDINE HCL H2O is used as an intermediate in the synthesis of various drugs and drug candidates. Its unique chemical structure contributes to the development of new therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Chemical Research:
4-FLUORO-BENZAMIDINE HCL H2O is also utilized in chemical research as a tool to study and understand the properties and behavior of different chemical compounds. Its use in this context is driven by its ability to interact with a variety of other molecules, providing valuable insights into chemical reactions and mechanisms.
Used in Material Science:
In the field of material science, 4-FLUORO-BENZAMIDINE HCL H2O is employed in the development of new materials with specific properties. Its incorporation into various materials can result in improved performance characteristics, such as enhanced stability, reactivity, or selectivity, depending on the desired application.

InChI:InChI=1/C7H7FN2.ClH.H2O/c8-6-3-1-5(2-4-6)7(9)10;;/h1-4H,(H3,9,10);1H;1H2

Upstream product

• 67-56-1 methanol 
• 1194-02-1 4-fluorobenzonitrile 
• 456-14-4 4-fluorobenzamidine hydrochloride 

Downstream Products

• 76128-79-5 4-hydroxy-2-(p-fluorophenyl)pyrimidine 
• 115127-46-3 bromo(4-fluorophenyl)diazirine 
• 191158-31-3 [2-(4-Fluoro-phenyl)-3H-imidazol-4-yl]-methanol 
• 30748-58-4 2-(4-fluoro-phenyl)-4-hydroxy-pyrimidine-5-carboxylic acid ethyl ester 
• 886761-29-1 4-amino-5-cyano-2-(p-fluorophenyl)-6-(p-nitrophenyl)pyrimidine 
• 30748-63-1 4-chloro-2-(4-fluoro-phenyl)-pyrimidine-5-carboxylic acid ethyl ester 
• 1027964-87-9 5-Chloromethyl-2-(4-fluoro-phenyl)-1H-imidazole 
• 76128-71-7 4-chloro-2-(p-fluorophenyl)pyrimidine 
• 76128-73-9 4-bromo-2-(p-fluorophenyl)pyrimidine 
• 76128-75-1 4-methoxy-2-(p-fluorophenyl)pyrimidine 
• 76144-36-0 4-cyano-2-(p-fluorophenyl)pyrimidine 
• 76128-76-2 4-dimethylamino-2-(p-fluorophenyl)pyrimidine 
• 76128-81-9 <2-(p-fluorophenyl)-4-pyrimidyl>trimethylammonium chloride 
• 116548-93-7 (4-fluorophenyl)methoxydiaziridine 

Relevant academic research and scientific papers

Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation

Based on the novel allosteric site of deoxyhypusine synthase (DHPS), two series of 30 novel 5-(2-methoxyphenoxy)-2-phenylpyrimidin-4-amine derivatives as DHPS inhibitors were designed and synthesized. Among them, compound8m, with the best DHPS inhibitory potency (IC50= 0.014 μM), exhibited excellent inhibition against melanoma cells, which was superior to that of GC7. Besides, molecular docking and molecular dynamics (MD) simulations further proved that compound8mwas tightly bound to the allosteric site of DHPS. Flow cytometric analysis and enzyme-linked immunosorbent assay (ELISA) showed that compound8mcould inhibit the intracellular reactive oxygen species (ROS) level. Furthermore, by western blot analysis, compound8meffectively activated caspase 3 and decreased the expressions of GP-100, tyrosinase, eIF5A2, MMP2, and MMP9. Moreover, both Transwell analysis and wound healing analysis showed that compound8mcould inhibit the invasion and migration of melanoma cells. In thein vivostudy, the tumor xenograft model showed that compound8meffectively inhibited melanoma development with low toxicity.

HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and a good inhibitory activity against autotaxin (ATX).

Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes

As a potential treatment of type 2 diabetes, a novel PPARγ non-TZD full agonist, compound 18 (BR102375) was identified from the original lead BR101549 by the SAR efforts of the labile metabolite control through bioisosteres approach. In vitro assessments

The amidine using triazine compound production (by machine translation)

[A] used in the synthesis of charge transport materials useful as the organic electroluminescent element of simple and inexpensive manufacturing method a triazine compound. Acyl amidine compound or an acid compound [a], the compound is preferably reacted in the presence of an amidine compound [...], the triazine compound of the formula illustrated in manufacture. [Drawing] no (by machine translation)

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS

This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES

The present invention relates to 2-phenyl-4-cyclopropyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular a

Novel Biccyclic Compounds As GATA Modulators

Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided.